Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study.
Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of anticoagulant, assay type and storage on the measurement of PTH in blood specimens.
Summary of Findings
Anticoagulant and assay type significantly affected the measured PTH variability (both p<0.001), but storage did not. While interindividual variability accounted for 96.8% of the variability, 2.5% of the variability was attributed to kit and 0.7% to anticoagulant. Citrated plasma consistently had lower levels of PTH than EDTA plasma and serum. Importantly, the differences in anticoagulant and kit type led to different Kidney Disease Outcomes Quality Initiative (KDOQI) classifications.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
FrozenDiagnoses
Diabetes Type 2Not specifiedPlatforms
PeptideClinical chemistry/auto analyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Anticoagulant EDTANoneSodium citrateBiospecimen Aliquots and Components Blood and blood products PlasmaSerumStorage Time at room temperature 0 h16-22 hClinical chemistry/auto analyzer Specific Technology platform Abbot AchitectBayer Advia CentaurBeckman-Coulter AccessDPC ImmuliteDiaSorin LIASONRoche Elecsys